At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
In Brief
A Phase 2 clinical trial evaluating Carfilzomib, Dexamethasone, and 1 other intervention for Metastatic Castration-resistant Prostate Cancer. Completed, enrolled 28 participants across 4 sites.
Detailed Summary
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors. Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer. Therefore, it is considered investigational. Other approved methods of treatment for metastatic prostate cancer have demonstrated only modest benefits. Novel and tolerable agents are necessary to make further gains and extend overall survival.
Study Details
Timeline
Interventions
Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
Administered prior to administration of Study drug
Administered orally twice daily